Samsung Biologics has entered into an agreement with biotech Dinona, further expanding its capabilities to provide a full scope of development services from cell line development, process development, to non-clinical and clinical material manufacturing. The companies will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy. Samsung’s contract development business has been growing with close to 60 contracts signed in just two years. The business segment co...